Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability

International Journal of Cancer

Volumn 127, Issue 2, 2010, Pages 474-484

  Li, Ying Yi ^a,b,c   Wang, Ying Ying ^c   Taniguchi, Tsuyoshi ^c   Kawakami, Takahiro ^c   Baba, Tomohisa ^c   Ishibashi, Hiroyuki ^c   Mukaida, Naofumi ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bad; Pim kinase

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE PIM 1; PROTEIN PIM 2; PROTEIN PIM 3; PROTEIN SERINE THREONINE KINASE; STEMONAMIDE; UNCLASSIFIED DRUG; BAD PROTEIN, HUMAN; PROTO ONCOGENE PROTEINS PIM; PROTO-ONCOGENE PROTEINS PIM; SPIRO COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENDODERM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953720785     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25048     Document Type: Article

References (40)

1. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C. Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 2004;16:265-74.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
3. Giza CC, Prins ML, Hovda DA, Herschman HR, Feldman JD. Genes preferentially induced by depolarization after concussive brain injury: effects of age and injury severity. J Neurotrauma 2002;19:387-402.
4. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT. PIM3 protooncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol 2003;23:3897-908. (Pubitemid 36597468)
5. Fujii C, Nakamoto Y, Lu P, Tsuneyama K, Popivanova BK, Kaneko S, Mukaida N. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 2005;114:209-18.
6. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a protooncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006;66:6741-7.
7. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N. Proto-oncogene. Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007;98:321-8.
8. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol 2008;134:481-8.
9. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989;56:673-82.
10. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443-51.
11. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the proapoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43-9.
12. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358-67.
13. Taniguchi T, Tanabe G, Muraoka O, Ishibashi H. Total synthesis of (+/-)- stemonamide and (+/-)-isostemonamide using a radical cascade. Org Lett 2008;10:197-9.
14. Yano T, Ishikura H, Kato H, Ogawa Y, Kondo S, Kato H, Yoshiki T. Vaccination effect of interleukin-6-producing pancreatic cancer cells in nude mice: a model of tumor prevention and treatment in immune-compromised patients. Jpn J Cancer Res 2001;92:83-7.
15. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975;15:741-7.
16. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977;19:128-35.
17. Leibovitz A, Stinson JC, McCombs WB, III, McCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976;36:4562-9.
18. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50-62.
19. Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 1977;58:1743-51.
20. Brattain MG, Brattain DE, Fine WD, Khaled FM, Marks ME, Kimball PM, Arcolano LA, Danbury BH. Initiation and characterization of cultures of human colonic carcinoma with different biological characteristics utilizing feeder layers of confluent fibroblasts. Oncodev Biol Med 1981;2:355-66.
21. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497-9.
22. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-63.
23. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115:2618-24.
24. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008;68:2366-74.
25. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-8.
26. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005;25:1869-78.
27. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 2004;113:441-50. (Pubitemid 38544188)
28. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41. (Pubitemid 27456390)
29. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-15. (Pubitemid 38787993)
30. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006;58:231-41. (Pubitemid 43796083)
31. Pilli RA, Ferreira de Oliveira MC. Recent progress in the chemistry of the Stemona alkaloids. Nat Prod Rep 2000;17:117-27.
32. Bullock AN, Debreczeni JE, Fedorov OY, Nelson A, Marsden BD, Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem 2005;48:7604-14. (Pubitemid 41698801)
33. Cheney IW, Yan S, Appleby T, Walker H, Vo T, Yao N, Hamatake R, Hong Z, Wu JZ. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007;17:1679-83. (Pubitemid 46274341)
34. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007;6:163-72. (Pubitemid 46206679)
35. Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007;67:6916-24.
36. Tong Y, Stewart KD, Thomas S, Przytulinska M, Johnson EF, Klinghofer V, Leverson J, McCall O, Soni NB, Luo Y, Lin NH, Sowin TJ, et al. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett 2008;18:5206-8.
37. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009;52:74-86.
38. Domen J, van der Lugt NM, Laird PW, Saris CJ, Clarke AR, Hooper ML, Berns A. Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells. Blood 1993;82:1445-52. (Pubitemid 23263960)
39. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005;105:4477-83.
40. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280:41675-82. (Pubitemid 43000572)